Triochem Products achieved a net profit of ₹9.48 lakh in the quarter ended June 2026, marking a significant turnaround from the net loss of ₹3.06 lakh recorded in the corresponding quarter of the previous financial year. According to the latest unaudited standalone financial results approved by the Board of Directors on August 14, 2026, this represents a complete reversal of the company's financial performance during the same period last year. The profit stems entirely from other income of ₹16.56 lakh against reduced expenses, with revenue from operations remaining at zero.
The company reported zero sales for both the quarter ended June 2026 and the corresponding quarter of the previous financial year. As reported in the latest financial results, this indicates that Triochem Products has not generated any revenue from its core chemical and pharmaceuticals segment during the current quarter, maintaining the same revenue position as the year-ago period. The company's total income of ₹16.56 lakh was derived entirely from other income sources.
The net profit of ₹9.48 lakh in Q1 FY27 represents a substantial improvement from the net loss of ₹3.06 lakh recorded in Q1 FY26. According to the financial results, total expenses were significantly reduced to ₹4.17 lakh in Q1 FY27, down from ₹37.34 lakh in the corresponding quarter of the previous year. This reduction was primarily driven by lower employee benefit expenses (₹0.75 lakh vs ₹13.52 lakh) and other expenditure (₹3.42 lakh vs ₹22.18 lakh). The company's earnings per share (EPS) stood at ₹3.87, compared to a loss of ₹1.25 per share in the previous year's quarter.
The current quarter's profitability is entirely non-operational, driven by other income exceeding minimal operational costs. As reported in the company's previous financial year results, Triochem had approved the sale of certain immovable properties, plant, machinery, and investment properties in Maharashtra, with shareholder approval obtained in December 2025. The assets with a written-down value of ₹56.92 lakh were sold for a fair market value of approximately ₹1,173.20 lakh, resulting in an exceptional gain of ₹1,116.65 lakh recognized in the previous financial year. The proceeds are proposed to be utilized for funding new business ventures and strategic initiatives, highlighting the company's transition phase where core business activities have effectively paused while management focuses on asset monetization and potential new ventures.
During the board meeting, directors discussed the ongoing impact of the post-COVID-19 pandemic on the business model, noting that sectors requiring personal presentation and relationship building have faced a "tremendous hit" with no immediate possibility of revival. The company confirmed that regular customer business is shrinking, with no significant improvement expected in the near term. The sharp decline in expenses suggests a lean operational structure maintained during this period of low activity, with the company's investment strategy evolving toward a cash-rich holding structure focused on strategic initiatives. The financial results were reviewed by the Audit Committee and approved by the Board in compliance with SEBI regulations, with statutory auditors Kanu Doshi Associates LLP issuing an unqualified conclusion on the quarterly results.
